Aryl hydrocarbon receptor agonist, leflunomide, protects the ischemic-reperfused kidney

Role of Tregs and stem cells

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The aryl hydrocarbon receptor (AHR) has emerged as a major modulator of inflammatory processes. We tested the hypothesis that AHR activation protects the ischemic-reperfused kidney in association with the suppression of the inflammatory response. Accordingly, male mice were treated with the nondioxin AHR agonist, leflunomide (40 mg/kg ip); vehicle-treated animals served as controls. Thereafter, the right kidney was subjected to an ischemia (45 min)-reperfusion (4 h) insult, while the left kidney served as a sham control. Renal cells prepared from ischemic-reperfused kidneys of leflunomide-treated mice displayed preservation of mitochondrial membrane potential (Ψm) and decreased apoptosis and necrosis compared with vehicle-treated ischemic-reperfused kidneys. Leflunomide treatment increased regulatory T cells (Tregs; forkhead box P3+) and IL-10-positive cells but reduced IL-17- and IL-23-expressing cells in both the peripheral blood and kidney cells, indicative of down-regulation of inflammatory responses. Leflunomide treatment also increased mobilization of stems cells subsets (i.e., mesenchymal and hematopoietic stem cells and endothelial progenitor cells) in the peripheral blood and promoted their recruitment into the ischemic-reperfused kidney. Collectively, the results indicate that AHR stimulation may represent a novel renoprotective mechanism likely involving mobilization and recruitment of Tregs and stem cells into the damaged kidney.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume303
Issue number11
DOIs
StatePublished - Dec 10 2012

Fingerprint

leflunomide
Aryl Hydrocarbon Receptors
Stem Cells
Kidney
Hematopoietic Stem Cell Mobilization
Interleukin-23
Interleukin-17
Mitochondrial Membrane Potential
Regulatory T-Lymphocytes
Hematopoietic Stem Cells
Mesenchymal Stromal Cells

Keywords

  • Aryl hydrocarbon receptor
  • Cell death
  • Interleukin
  • Ischemia-reperfusion
  • Kidney
  • Mitochondrial membrane potential
  • Regulatory T cells
  • Stem cells

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

@article{6480a5a0f2384bd1a02928b0b6f3713b,
title = "Aryl hydrocarbon receptor agonist, leflunomide, protects the ischemic-reperfused kidney: Role of Tregs and stem cells",
abstract = "The aryl hydrocarbon receptor (AHR) has emerged as a major modulator of inflammatory processes. We tested the hypothesis that AHR activation protects the ischemic-reperfused kidney in association with the suppression of the inflammatory response. Accordingly, male mice were treated with the nondioxin AHR agonist, leflunomide (40 mg/kg ip); vehicle-treated animals served as controls. Thereafter, the right kidney was subjected to an ischemia (45 min)-reperfusion (4 h) insult, while the left kidney served as a sham control. Renal cells prepared from ischemic-reperfused kidneys of leflunomide-treated mice displayed preservation of mitochondrial membrane potential (Ψm) and decreased apoptosis and necrosis compared with vehicle-treated ischemic-reperfused kidneys. Leflunomide treatment increased regulatory T cells (Tregs; forkhead box P3+) and IL-10-positive cells but reduced IL-17- and IL-23-expressing cells in both the peripheral blood and kidney cells, indicative of down-regulation of inflammatory responses. Leflunomide treatment also increased mobilization of stems cells subsets (i.e., mesenchymal and hematopoietic stem cells and endothelial progenitor cells) in the peripheral blood and promoted their recruitment into the ischemic-reperfused kidney. Collectively, the results indicate that AHR stimulation may represent a novel renoprotective mechanism likely involving mobilization and recruitment of Tregs and stem cells into the damaged kidney.",
keywords = "Aryl hydrocarbon receptor, Cell death, Interleukin, Ischemia-reperfusion, Kidney, Mitochondrial membrane potential, Regulatory T cells, Stem cells",
author = "Babak Baban and Liu, {Jun Yao} and Mozaffari, {Mahmood S}",
year = "2012",
month = "12",
day = "10",
doi = "10.1152/ajpregu.00315.2012",
language = "English (US)",
volume = "303",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "11",

}

TY - JOUR

T1 - Aryl hydrocarbon receptor agonist, leflunomide, protects the ischemic-reperfused kidney

T2 - Role of Tregs and stem cells

AU - Baban, Babak

AU - Liu, Jun Yao

AU - Mozaffari, Mahmood S

PY - 2012/12/10

Y1 - 2012/12/10

N2 - The aryl hydrocarbon receptor (AHR) has emerged as a major modulator of inflammatory processes. We tested the hypothesis that AHR activation protects the ischemic-reperfused kidney in association with the suppression of the inflammatory response. Accordingly, male mice were treated with the nondioxin AHR agonist, leflunomide (40 mg/kg ip); vehicle-treated animals served as controls. Thereafter, the right kidney was subjected to an ischemia (45 min)-reperfusion (4 h) insult, while the left kidney served as a sham control. Renal cells prepared from ischemic-reperfused kidneys of leflunomide-treated mice displayed preservation of mitochondrial membrane potential (Ψm) and decreased apoptosis and necrosis compared with vehicle-treated ischemic-reperfused kidneys. Leflunomide treatment increased regulatory T cells (Tregs; forkhead box P3+) and IL-10-positive cells but reduced IL-17- and IL-23-expressing cells in both the peripheral blood and kidney cells, indicative of down-regulation of inflammatory responses. Leflunomide treatment also increased mobilization of stems cells subsets (i.e., mesenchymal and hematopoietic stem cells and endothelial progenitor cells) in the peripheral blood and promoted their recruitment into the ischemic-reperfused kidney. Collectively, the results indicate that AHR stimulation may represent a novel renoprotective mechanism likely involving mobilization and recruitment of Tregs and stem cells into the damaged kidney.

AB - The aryl hydrocarbon receptor (AHR) has emerged as a major modulator of inflammatory processes. We tested the hypothesis that AHR activation protects the ischemic-reperfused kidney in association with the suppression of the inflammatory response. Accordingly, male mice were treated with the nondioxin AHR agonist, leflunomide (40 mg/kg ip); vehicle-treated animals served as controls. Thereafter, the right kidney was subjected to an ischemia (45 min)-reperfusion (4 h) insult, while the left kidney served as a sham control. Renal cells prepared from ischemic-reperfused kidneys of leflunomide-treated mice displayed preservation of mitochondrial membrane potential (Ψm) and decreased apoptosis and necrosis compared with vehicle-treated ischemic-reperfused kidneys. Leflunomide treatment increased regulatory T cells (Tregs; forkhead box P3+) and IL-10-positive cells but reduced IL-17- and IL-23-expressing cells in both the peripheral blood and kidney cells, indicative of down-regulation of inflammatory responses. Leflunomide treatment also increased mobilization of stems cells subsets (i.e., mesenchymal and hematopoietic stem cells and endothelial progenitor cells) in the peripheral blood and promoted their recruitment into the ischemic-reperfused kidney. Collectively, the results indicate that AHR stimulation may represent a novel renoprotective mechanism likely involving mobilization and recruitment of Tregs and stem cells into the damaged kidney.

KW - Aryl hydrocarbon receptor

KW - Cell death

KW - Interleukin

KW - Ischemia-reperfusion

KW - Kidney

KW - Mitochondrial membrane potential

KW - Regulatory T cells

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84870491006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870491006&partnerID=8YFLogxK

U2 - 10.1152/ajpregu.00315.2012

DO - 10.1152/ajpregu.00315.2012

M3 - Article

VL - 303

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 11

ER -